Dyne Therapeutics, Inc. Amortization of Debt Discount (Premium)
Dyne Therapeutics, Inc. (DYN) reported Amortization of Debt Discount (Premium) of $64.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2022-03-10
- Dyne Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2020-06-30 was $1.00K.
- Dyne Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2020-03-31 was $12.00K.
- Dyne Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2020 was $64.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|
| 2020-12-31 | $64.00K 10-K · filed 2022-03-10 | ||
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $13.00K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |